Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties
Open Access
- 12 March 2008
- journal article
- Published by Springer Science and Business Media LLC in Journal of Molecular Medicine
- Vol. 86 (5), 585-596
- https://doi.org/10.1007/s00109-008-0322-6
Abstract
A wild-type (wt) p53 gene characterizes thyroid tumors, except for the rare anaplastic histotype. Because p53 inactivation is a prerequisite for tumor development, alterations of p53 regulators represent an alternative way to impair p53 function. Indeed, murine double minute 2 (MDM2), the main p53 negative regulator, is overexpressed in many tumor histotypes including those of the thyroid. A new p53 regulator, MDM4 (a.k.a. MDMX or HDMX) an analog of MDM2, represents a new oncogene although its impact on tumor properties remains largely unexplored. We estimated levels of MDM2, MDM4, and its variants, MDM4-S (originally HDMX-S) and MDM4-211 (originally HDMX211), in a group of 57 papillary thyroid carcinomas (PTC), characterized by wt tumor protein 53, in comparison to matched contra-lateral lobe normal tissue. Further, we evaluated the association between expression levels of these genes and the histopathological features of tumors. Quantitative real-time polymerase chain reaction revealed a highly significant downregulation of MDM4 mRNA in tumor tissue compared to control tissue ( P < 0.0001), a finding confirmed by western blot on a subset of 20 tissue pairs. Moreover, the tumor-to-normal ratio of MDM4 levels for each individual was significantly lower in late tumor stages, suggesting a specific downregulation of MDM4 expression with tumor progression. In comparison, MDM2 messenger RNA (mRNA) and protein levels were frequently upregulated with no correlation with MDM4 levels. Lastly, we frequently detected overexpression of MDM4-S mRNA and presence of the aberrant form, MDM4-211 in this tumor group. These findings indicate that MDM4 alterations are a frequent event in PTC. It is worthy to note that the significant downregulation of full-length MDM4 in PTC reveals a novel status of this factor in human cancer that counsels careful evaluation of its role in human tumorigenesis and of its potential as therapeutic target.Keywords
This publication has 28 references indexed in Scilit:
- MdmX Promotes Bipolar Mitosis To Suppress Transformation and Tumorigenesis in p53-Deficient Cells and MiceMolecular and Cellular Biology, 2008
- Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic studyBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2006
- Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4Cell Death & Differentiation, 2006
- Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate CancerMolecular Cancer Research, 2006
- Real-Time Quantitative PCR Analysis of Regions Involved in Gene Amplification Reveals Gene Overdose in Low-Grade Astrocytic GliomasDiagnostic Molecular Pathology, 2005
- Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 StabilizationCancer Research, 2005
- Significance of HDMX‐S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosisInternational Journal of Cancer, 2005
- A Novel MDMX Transcript Expressed in a Variety of Transformed Cell Lines Encodes a Truncated Protein with Potent p53 Repressive ActivityPublished by Elsevier BV ,1999
- The MDM2 gene amplification databaseNucleic Acids Research, 1998
- Nuclear Accumulation of MDM2 Protein in Well-Differentiated Papillary Thyroid CarcinomasExperimental and Molecular Pathology, 1995